Galera Therapeutics to Merge with Obsidian, Securing $350M Private Placement; Combined Entity to List on Nasdaq
Summary
Galera Therapeutics announced a definitive merger agreement with privately-held Obsidian Therapeutics in an all-stock transaction. Concurrently, the combined entity secured an oversubscribed private placement financing of $350 million. The combined company will operate as Obsidian Therapeutics, Inc. and plans to apply to trade on Nasdaq under the ticker "OBX." This transformative event directly addresses Galera's previously disclosed "going concern" warning from its last 10-K and follows recent SEC filings indicating significant corporate restructuring, including preferred share conversions and proposals for a reverse stock split. The $350 million private placement is highly material, representing over 100 times Galera's current market capitalization, effectively recapitalizing the company and providing a new strategic direction focused on Obsidian's engineered TIL cell therapies. This financing is expected to fund operations into the second half of 2028, through key clinical milestones for Obsidian's lead product candidate, OBX-115. Investors will monitor the closing of the merger and private placement, the new Nasdaq listing, and the progress of Obsidian's clinical trials, particularly the NSCLC Phase 1 data expected in 1H 2027 and melanoma registration-enabling data by year-end 2027.
At the time of this announcement, GRTX was trading at $0.04 on OTC in the Life Sciences sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $0.02 to $0.06. This news item was assessed with positive market sentiment and an importance score of 10 out of 10. Source: Dow Jones Newswires.